A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Cytarabine (Primary) ; Decitabine (Primary) ; PCM 075 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors TrovaGene
- 09 Oct 2017 According to a TrovaGene media release, this study was accepted by the National Library of Medicine (NLM).
- 02 Oct 2017 Planned number of patients changed from 60 to 116.
- 02 Oct 2017 Status changed from planning to not yet recruiting.